Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy

Key Points

• Examine the impact of CFTR modulator therapy on Burkholderia species infections in cystic fibrosis patients.
• Analyzed microbiological outcomes associated with Burkholderia species in cystic fibrosis patients.
• Evaluated the effects of CFTR modulator therapy (ETI) on infection dynamics.
• Assessed changes in infection acquisition and clearance rates post-treatment.
• ETI does not completely eliminate the risk of chronic Burkholderia infection.
• The therapy may aid in reducing new infections for some patients.
• Notable support for bacterial clearance observed in a subset of individuals.